BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...Management and existing investors Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners and MRL Ventures Fund.Diagnostics...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...on Hexagon. Existing LifeMine investors GV, WuXi Healthcare Ventures, Foresite Capital, Arch Ventures, Blue Pool Capital and MRL Ventures Fund...
...Klausner, Milky Way Investments, GV, WuXi Healthcare Ventures, Foresite Capital, Arch Ventures, Blue Pool Capital and MRL Ventures Fund, Boyu...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Inc. Existing investors AbbVie Ventures, HealthCap, Wellington Partners, IP Group, TPG Biotech, Agent Capital and MRL Ventures Fund...
...Capital Foresite Capital Qiming Venture Partners Carisma Therapeutics Inc. SymBiosis LLC Solasta Ventures Livzon Pharmaceutical Group Inc. AbbVie Ventures HealthCap Wellington Partners IP Group TPG Biotech Agent Capital MRL Ventures Fund argenx...
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...Venture, Lightstone Ventures, Matrix Partners China and MRL Ventures Fund.The...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...Capital Management LLC. Existing investors Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...Capital and BB Pureos Bioventures as well as returning investors Versant Ventures, Gilde Healthcare and MRL Ventures Fund.TARGETSCD1D Stephen...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...said SR One led the series B funding, which included new investors Tekla Capital Management, MRL Ventures Fund...
...SR One, which is the independent corporate venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), and MRL Ventures Fund...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...Takeda Ventures Inc. led the financing with participation from fellow new investors SV Health Investors, MRL Ventures Fund...
BioCentury | Mar 21, 2019
Financial News

Imago to deploy $40M series B for Phase II trials

...HighLight Capital, Pharmaron and Greenspring Associates along with existing investors Frazier Healthcare Partners, Amgen Ventures, MRL Ventures Fund...
BioCentury | Dec 21, 2018
Financial News

Entrada raises $59M series A to take intracellular biologic into clinic

...with new investor MPM Capital. The series A also attracted existing investors Roche Venture Fund, MRL Ventures Fund...
Items per page:
1 - 10 of 31
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...Management and existing investors Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners and MRL Ventures Fund.Diagnostics...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...on Hexagon. Existing LifeMine investors GV, WuXi Healthcare Ventures, Foresite Capital, Arch Ventures, Blue Pool Capital and MRL Ventures Fund...
...Klausner, Milky Way Investments, GV, WuXi Healthcare Ventures, Foresite Capital, Arch Ventures, Blue Pool Capital and MRL Ventures Fund, Boyu...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Inc. Existing investors AbbVie Ventures, HealthCap, Wellington Partners, IP Group, TPG Biotech, Agent Capital and MRL Ventures Fund...
...Capital Foresite Capital Qiming Venture Partners Carisma Therapeutics Inc. SymBiosis LLC Solasta Ventures Livzon Pharmaceutical Group Inc. AbbVie Ventures HealthCap Wellington Partners IP Group TPG Biotech Agent Capital MRL Ventures Fund argenx...
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...Venture, Lightstone Ventures, Matrix Partners China and MRL Ventures Fund.The...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...Capital Management LLC. Existing investors Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...Capital and BB Pureos Bioventures as well as returning investors Versant Ventures, Gilde Healthcare and MRL Ventures Fund.TARGETSCD1D Stephen...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...said SR One led the series B funding, which included new investors Tekla Capital Management, MRL Ventures Fund...
...SR One, which is the independent corporate venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), and MRL Ventures Fund...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...Takeda Ventures Inc. led the financing with participation from fellow new investors SV Health Investors, MRL Ventures Fund...
BioCentury | Mar 21, 2019
Financial News

Imago to deploy $40M series B for Phase II trials

...HighLight Capital, Pharmaron and Greenspring Associates along with existing investors Frazier Healthcare Partners, Amgen Ventures, MRL Ventures Fund...
BioCentury | Dec 21, 2018
Financial News

Entrada raises $59M series A to take intracellular biologic into clinic

...with new investor MPM Capital. The series A also attracted existing investors Roche Venture Fund, MRL Ventures Fund...
Items per page:
1 - 10 of 31